Quick Answer
MoonLake Immunotherapeutics reported R&D Expense of $202.86 million for fiscal year 2025.
MoonLake Immunotherapeutics R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $202.86M | +79.9% |
| 2024 | $112.77M | +254.6% |
| 2023 | $31.80M | -24.4% |
| 2022 | $42.05M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $60.63M | +69.7% | +21.9% |
| June 30, 2025 | $49.76M | +110.3% | +36.5% |
| March 31, 2025 | $36.46M | +180.2% | +2.0% |
| September 30, 2024 | $35.74M | +371.1% | +51.0% |
| June 30, 2024 | $23.66M | +171.9% | +81.8% |
| March 31, 2024 | $13.01M | +75.5% | +71.6% |
| September 30, 2023 | $7.59M | -15.9% | -12.9% |
| June 30, 2023 | $8.70M | -23.7% | +17.4% |
- MoonLake Immunotherapeutics showed an increase of +79.9% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, MoonLake Immunotherapeutics’s r&d expense has grown by 382.4% (from $42.05 million to $202.86 million).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: